Samokhvalov Andriy V, Rehm Jürgen
Social & Epidemiological Research Department, Centre for Addiction and Mental Health, Toronto, Canada Addictions Program, Centre for Addiction and Mental Health, Toronto Canada.
Social & Epidemiological Research Department, Centre for Addiction and Mental Health, Toronto, Canada.
BMJ Case Rep. 2015 Nov 13;2015:bcr2015211954. doi: 10.1136/bcr-2015-211954.
Opioid-induced constipation (OIC) is one of the major side effects in patients receiving methadone maintenance treatment (MMT). Quite often, constipation becomes a factor significantly affecting therapeutic options and choices. Currently used approaches are symptomatic and in many cases ineffective. At the same time, it is well known that the gastrointestinal system is a subject for psychosomatic influences. In this case report, we describe an unexpected outcome of placebo administration in a patient suffering from OIC since her participation in MMT. The patient participated in a triple-blind randomised placebo-controlled trial of naloxone for treatment of OIC. As part of the study crossover design, the patient received 1 week of placebo followed by 1 week of naloxone, and had significant improvement in her bowel functioning when receiving placebo, then returned to baseline during the second week of the study.
阿片类药物引起的便秘（OIC）是接受美沙酮维持治疗（MMT）患者的主要副作用之一。便秘常常成为显著影响治疗方案和选择的一个因素。目前使用的方法只是对症治疗，在很多情况下并无效果。同时，众所周知，胃肠系统是受身心影响的一个对象。在本病例报告中，我们描述了一名自参加MMT以来一直患有OIC的患者使用安慰剂后的意外结果。该患者参与了一项关于纳洛酮治疗OIC的三盲随机安慰剂对照试验。作为研究交叉设计的一部分，该患者先接受了1周的安慰剂治疗，随后接受了1周的纳洛酮治疗，在接受安慰剂治疗时其肠道功能有显著改善，然后在研究的第二周又恢复到了基线水平。
